Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.74 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.74 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.63 |
| ▸ | CCND1 | P24385 | 1/20 | 0.63 |
| ▸ | CCNC | P24863 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | CDK7 | P50613 | 1/20 | 0.63 |
| ▸ | CDK9 | P50750 | 1/20 | 0.63 |
| ▸ | CCNH | P51946 | 1/20 | 0.63 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.63 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 3/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187396 | 0.86 | MKNK2 (0.56) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL30108206 | 0.85 | MKNK2 (0.58) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL18943848 | 0.85 | MAP4K4 (1.00) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL26613435 | 0.85 | CA12 (0.60) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL947559 | 0.81 | CCNT1 (0.54) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL3113403 | 0.81 | KMT2A (0.64) | JAK3 | |
| SCHEMBL30323720 | 0.81 | BIRC5 (0.77) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL27631118 | 0.81 | BIRC5 (0.77) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL944311 | 0.79 | PDGFRB (0.58) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 | |
| SCHEMBL29362497 | 0.79 | MGAM (0.71) | CSNK1G2CLK4MAP4K4MKNK2MAP4K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9586932-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8598360-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CSNK1G2 725/4885CLK4 1767/4885MAP4K4 115/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CSNK1G2 725/4885CLK4 1767/4885MAP4K4 115/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | CSNK1G2 654/4885CLK4 1829/4885MAP4K4 120/4885 |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | CSNK1G2 3682/4885CLK4 4199/4885MAP4K4 2317/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CSNK1G2 725/4885CLK4 1767/4885MAP4K4 115/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | CSNK1G2 658/4885CLK4 1634/4885MAP4K4 107/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | CSNK1G2 725/4885CLK4 1767/4885MAP4K4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.